Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukaemia – physicochemical characteristics, in vitro mechanistic studies and ex vivo patient derived therapeutic efficacy

Caitriona O'Driscoll

doi:10.1021/acs.molpharmaceut.6b01150

Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukaemia – physicochemical characteristics, in vitro mechanistic studies and ex vivo patient derived therapeutic efficacy

Caitriona O'Driscoll

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Molecular Pharmaceutics
DOIs	https://doi.org/10.1021/acs.molpharmaceut.6b01150
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acs.molpharmaceut.6b01150

Cite this

@article{3821d660858f49a7aa420738e895f8b1,

title = "Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukaemia – physicochemical characteristics, in vitro mechanistic studies and ex vivo patient derived therapeutic efficacy",

author = "Caitriona O'Driscoll",

year = "2017",

doi = "10.1021/acs.molpharmaceut.6b01150",

language = "English",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

}

TY - JOUR

T1 - Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukaemia – physicochemical characteristics, in vitro mechanistic studies and ex vivo patient derived therapeutic efficacy

AU - O'Driscoll, Caitriona

PY - 2017

Y1 - 2017

U2 - 10.1021/acs.molpharmaceut.6b01150

DO - 10.1021/acs.molpharmaceut.6b01150

M3 - Article

SN - 1543-8384

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

ER -